Boston gets back on track as Irish plant in the clear
This article was originally published in Clinica
Executive Summary
Following a seven-day US FDA inspection of Boston Scientific's Galway, Ireland-based factory, the agency has reported that no observations were made at the facility where the company's Taxus Express2 drug-eluting stent (DES) is manufactured. The inspection was carried out as part of the ongoing investigation into the worldwide recall of nearly 100,000 Taxus DESs throughout July and August. The FDA has already given Boston's other DES plant in Maple Grove, Minnesota the all-clear when it inspected the facility in July.
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.